Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
The data with the CRISPR/Cas9 drug CTX001 is still very early ... to use the gene-editing technology as a one-shot treatment for serious diseases. All seven thalassaemia patients were seriously ...
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...
CRISPR technology has revolutionized ... these tools can guide tailored treatment strategies and preventive measures. Furthermore, real-time disease monitoring could become a reality, allowing ...
Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...
According to InvestingPro data, the company maintains ... As the company leverages its proprietary CRISPR/Cas9 platform to address serious diseases, investors and analysts are closely watching ...
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback